HM Venture Partners
- Company typePrivate
- Founded2019
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
HM Venture Partners firmographics
Firmographics- Name
- HM Venture Partners
- Legal name
- HM Venture Partners
- Website
- https://hmventurepartners.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
HM Venture Partners industry classification
Industry- Product category
- Venture Capital (Healthcare)
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
Keywords
Where HM Venture Partners is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
HM Venture Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Fund Management Fees: Collects management fees from its three funds under management as a standard VC practice
- Carried Interest/Performance Fees: Earned through successful exits and returns from portfolio companies such as OncoImmune (acquired by Merck), KBP (acquired by Novo Nordisk), Urotronic (acquired by Laborie), Arthrosi (acquired by Sobi), and Sagimet (IPO)
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
HM Venture Partners product offering
Product offeringCore offering
HM Venture Partners is a healthcare venture capital firm that invests equity capital from its three funds (HM Healthcare Fund I, II, and III) into early and growth-stage biotech and medtech companies globally. Beyond capital, the firm provides operational support, strategic advisory, FDA approval guidance, clinical trial site access, and introductions to distribution channels including the Chinese market, leveraging its Mayo Clinic and Hillhouse ecosystem.
Product overview
HM Venture Partners operates as a healthcare venture capital firm managing three investment funds (HM Healthcare Fund I, II, and III) with combined AUM exceeding $600M. The firm provides investment services to early and growth-stage biotech and medtech companies globally. Their investment offering includes capital deployment, operational support, and leveraging their ecosystem of academic institutions, physician networks, and industry experts to support portfolio companies.
Differentiator
Problem solved
Functional benefit
Brands
- HM Healthcare Fund I: Third fund launched to primarily invest in healthcare breakthroughs in the US
- HM Healthcare Fund II
- HM Healthcare Fund III
Products and services
- HM Healthcare Fund I Healthcare-focused venture capital fund under HM Venture Partners management, primarily investing in healthcare breakthroughs in the US market.
- HM Healthcare Fund II Second healthcare-focused investment fund under HM Venture Partners management.
- HM Healthcare Fund III Third healthcare-focused investment fund under HM Venture Partners management; one of three funds contributing to combined AUM in excess of $600M.
Quantifiable outcome
- OncoImmune acquired by Merck for $425M upfront plus milestones and spin-off shares
- +3 more outcomes
Companies that use HM Venture Partners
Customer profileSegments2 records
Ideal customer profiles2 records
HM Venture Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
HM Venture Partners partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Mayo CliniccoreCo-founded HM Healthcare Management Services (HMHMS) with Hillhouse Investment Group and Mayo Clinic in 2014. This partnership established HM Venture Partners' foundational relationship with Mayo Clinic, enabling access to clinical networks, deal flow, and co-investment opportunities. Mayo Clinic physicians and business leaders are investors in HM's funds.
- Hillhouse Investment GroupcoreCo-founded HM Healthcare Management Services (HMHMS) with Hillhouse Investment Group and Mayo Clinic in 2014. Hillhouse provides capital and resources that support HM's investment activities.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
HM Venture Partners competitors and assessment
Company assessmentBroad incumbents
- OrbiMed: OrbiMed is the world's largest healthcare-dedicated investment firm, investing across all stages from venture through public markets. Comparable as a sector-focused healthcare VC incumbent competing for the same biotech/medtech deals and LP capital.
- RA Capital Management: RA Capital is a multi-stage healthcare investment manager combining public and private healthcare investing. Comparable as a large healthcare-focused peer with both fund-of-funds and direct investment capabilities serving similar LPs.
- ARCH Venture Partners: ARCH is one of the largest and most established US biotech/medtech venture firms, investing across stages with deep ties to academic institutions. Comparable as a healthcare-specialist incumbent with academic-ecosystem deal sourcing akin to HMVP's Mayo Clinic relationship.
Direct peers
- Atlas Venture: Atlas Venture is an early-stage biotech-focused venture firm that builds companies from inception. Comparable as a healthcare-specialist VC of similar scale focused on company formation and Series A biotech investing.
- Vivo Capital: Vivo Capital is a US healthcare-focused venture and growth firm with strong cross-border US–Asia capability. Directly comparable to HMVP given its similar sector specialization, multi-fund structure, and emphasis on healthcare investments spanning biotech, medtech, and cross-border opportunities.
- Third Rock Ventures: Third Rock Ventures is a healthcare-focused VC that builds biotech companies from inception with deep ties to academic medical centers. Comparable as a healthcare-specialist firm with academic-medical-center sourcing analogous to HMVP's Mayo Clinic ecosystem.
- 5AM Ventures: 5AM Ventures is a healthcare-focused early-stage venture firm investing in biotech and medtech. Comparable as a similarly sized healthcare specialist competing in Series A–B rounds across the same therapeutic areas as HMVP.
- Versant Ventures: Versant is a healthcare-focused VC firm investing in biotech, medtech, and healthcare services across stages. Comparable given its dedicated healthcare focus, multiple funds, and emphasis on building companies from inception, similar to HMVP's Mayo-rooted strategy.
- Sofinnova Investments: Sofinnova is a healthcare-specialist VC with decades of experience in biotech and medtech investing across stages. Comparable as a similarly sized sector-focused peer with cross-stage healthcare strategies targeting similar therapeutic and device themes.
Regional players
- Forbion: Forbion is a leading European healthcare-dedicated VC firm investing in biotech and medtech. Comparable as a healthcare-specialist VC with multi-fund AUM and similar stage focus, though primarily serves the European ecosystem.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
HM Venture Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
HM Venture Partners leadership team
Management profileNumber of profiles
Profiles7 records
HM Venture Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HM Venture Partners M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HM Venture Partners
What does HM Venture Partners do?
HM Venture Partners is a healthcare venture capital firm that invests equity capital from its three funds (HM Healthcare Fund I, II, and III) into early and growth-stage biotech and medtech companies globally. Beyond capital, the firm provides operational support, strategic advisory, FDA approval guidance, clinical trial site access, and introductions to distribution channels including the Chinese market, leveraging its Mayo Clinic and Hillhouse ecosystem.
Is HM Venture Partners a public or private company?
HM Venture Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was HM Venture Partners founded?
HM Venture Partners was founded in 2019. It employs 11 to 50 people.
Where is HM Venture Partners based?
HM Venture Partners is headquartered in San Francisco, United States, in the North America region.
How does HM Venture Partners make money?
Two revenue lines are on record. Fund Management Fees are the primary driver. The others are carried Interest/Performance Fees.
Who are HM Venture Partners's main competitors?
Broad incumbents on record are OrbiMed, RA Capital Management and ARCH Venture Partners. Direct peers are Atlas Venture, Vivo Capital, Third Rock Ventures, 5AM Ventures, Versant Ventures and Sofinnova Investments. Forbion is listed as a regional player.
Does HM Venture Partners have an API?
No public API is recorded for HM Venture Partners.
What industry is HM Venture Partners in?
HM Venture Partners's product category is Venture Capital (Healthcare). Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.